FESILTY
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- FESILTY
- Generic name
- FIBRINOGEN, HUMAN-CHMT
- Manufacturer
- Grifols USA LLC
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 1b470116-54bc-4ef8-ae46-2fba06c3368b
- SPL ID
- be4e2748-8d18-4593-9855-c2c4f3faba3e
- Version
- 5
- Effective date
- 2026-08-20
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:33
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125833 | derived:openfda.application_number |
| application number | BLA125833 | openfda.application_number | |
| brand name | FESILTY | openfda.brand_name | |
| generic name | FIBRINOGEN, HUMAN-CHMT | openfda.generic_name | |
| manufacturer name | Grifols USA LLC | openfda.manufacturer_name | |
| ndc | package | 13533-502-01 | openfda.package_ndc |
| ndc | package | 13533-503-02 | openfda.package_ndc |
| ndc | package | 13533-200-50 | openfda.package_ndc |
| ndc | product | 13533-502 | openfda.product_ndc |
| ndc11 | package | 13533020050 | derived:openfda.package_ndc |
| ndc11 | package | 13533050201 | derived:openfda.package_ndc |
| ndc11 | package | 13533050302 | derived:openfda.package_ndc |
| rxcui | 2730332 | openfda.rxcui | |
| rxcui | 2730338 | openfda.rxcui | |
| spl id | be4e2748-8d18-4593-9855-c2c4f3faba3e | id | |
| spl set id | 1b470116-54bc-4ef8-ae46-2fba06c3368b | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions have occurred in patients receiving FESILTY. Should symptoms occur, discontinue FESILTY and administer appropriate treatment. ( 5.1 ) Thrombotic events have been reported in patients receiving FESILTY. Weigh the benefits of administration versus the risks of thrombosis. ( 5.2 ) FESILTY is made from pooled human plasma and may carry the risk of transmitting infectious agents. All infections thought to be transmitted by FESILTY should be reported to Grifols at 1-800-520-2807, ( 5.3 ) 5.1 Hypersensitivity Hypersensitivity reactions have occurred to FESILTY or its components (arginine hydrochloride, polysorbate 80, sodium citrate dihydrate, trehalose dihydrate). Monitor patients for signs and symptoms of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If symptoms occur, discontinue FESILTY infusion immediately. Manage patients based on clinical practice accordingly. 5.2 Thrombosis Thrombotic events have occurred in patients receiving FESILTY [see Adverse Reactions (6) ]. Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy. Weigh the benefits of FESILTY administration versus the risks of thrombosis. Monitor patients receiving FESILTY for signs and symptoms of thrombosis. 5.3 Transmissible Infectious Agents Because FESILTY is made from pooled human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. The risk of infectious agent transmission has been reduced by screening plasma donors and by including virus inactivation as well as virus and prion removal steps in the manufacturing process of FESILTY [see Description (11) ]. All infections suspected to have been transmitted by FESILTY should be reported by the physician or other healthcare provider to Grifols at 1-800-520-2807.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence > 2%) were pain in extremity, back pain, hypersensitivity reactions, pyrexia, thrombosis, fibrin D dimer increased, headache, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data described in this section reflects exposure to FESILTY in one clinical study (Study 984). A total of 45 patients with congenital fibrinogen deficiency received at least one dose of FESILTY. A total of 175 bleeding episodes were treated with a mean dose of 3.9 g [see Clinical Studies (14) ]. Serious adverse reactions occurred in 4 patients (9%) including portal vein thrombosis (n=1), deep vein thrombosis (n=1), and pain in extremity with clinically suspected thrombosis (n=1). One patient had episode of epilepsy and died due to extradural hematoma four weeks after FESILTY administration. Table 2 lists the most common adverse reactions that occurred in > 2% patients in Study 984. Table 2: Adverse Reactions Occurring in > 2% Patients in Study 984 Adverse Reaction N=45 n (%) Pain in extremity 3 (7) Back pain 3 (7) Hypersensitivity reactions Hypersensitivity reactions = all patients had adverse reactions of facial swelling. 3 (7) Pyrexia 2 (4) Thrombosis Thrombosis includes portal vein thrombosis and deep vein thrombosis. 2 (4) Fibrin D dimer increased 2 (4) Headache 2 (4) Vomiting 2 (4)
adverse reactions table
<table ID="SPLSERV-5fb503ca-1040-44bd-b317-8a79d4931283" cellpadding="4" styleCode="Noautorules" width="50%"><caption>Table 2: Adverse Reactions Occurring in > 2% Patients in Study 984</caption><colgroup><col align="center" styleCode="Botrule Lrule Rrule Toprule"/><col align="center" styleCode="Botrule Lrule Rrule Toprule"/></colgroup><thead><tr><th align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">Adverse Reaction</content></th><th align="center" styleCode="Botrule Lrule Rrule Toprule"><content styleCode="bold">N=45 </content><content styleCode="bold">n (%)</content></th></tr></thead><tbody><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Pain in extremity</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (7)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Back pain</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (7)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Hypersensitivity reactions<footnote ID="SPLSERV-123800FA-64BD-7F4F-FAD8-A12BBE75F427">Hypersensitivity reactions = all patients had adverse reactions of facial swelling.</footnote></td><td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (7)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Pyrexia</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (4)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Thrombosis<footnote ID="SPLSERV-EA7A9953-6248-7BBA-9034-810680153843">Thrombosis includes portal vein thrombosis and deep vein thrombosis.</footnote></td><td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (4)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Fibrin D dimer increased</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (4)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Headache</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (4)</td></tr><tr><td align="center" styleCode="Botrule Lrule Rrule Toprule">Vomiting</td><td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (4)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.